Bruker (NASDAQ:BRKR) Issues Earnings Results

Bruker (NASDAQ:BRKR) issued its quarterly earnings results on Tuesday. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11, Zacks reports. The firm had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $0.32 EPS. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Positive Sentiment: Bruker returned to organic revenue growth in Q2, with revenue up 5.2% year over year and organic bookings growth of 10%; biopharma bookings rose more than 20%, while semiconductor metrology and energy research orders grew more than 50%.
• Positive Sentiment: Cost reductions, favorable mix and volume drove a 510-basis-point increase in non-GAAP operating margin to 14.1%, while non-GAAP EPS rose 53% to $0.49. The company remains on track for $140 million in annualized 2026 savings and expects an additional $20 million of savings from its new operating structure in 2027.
• Positive Sentiment: Management reiterated its 2026 outlook, including 1%-2% organic revenue growth, 250-300 basis points of operating-margin expansion and non-GAAP EPS of $2.10-$2.15, representing 15%-17% growth. Executives also expect further margin expansion and double-digit EPS growth in 2027.
• Negative Sentiment: U.S. academic and government demand remained weak, contributing to a more than $15 million year-over-year revenue decline in that market during Q2, while Asia-Pacific revenue fell by low double digits. A $135 million non-cash goodwill impairment tied to the loss-making automation and spatial biology businesses resulted in a GAAP diluted loss of $0.41 per share.
• Neutral Sentiment: About $20 million of semiconductor revenue is shifting from Q3 into Q4 due to customer delivery requirements, leading management to expect Q3 organic revenue to be roughly flat to slightly up and sequentially lower margins and EPS. The company expects a significantly stronger Q4, supported by semiconductor deliveries, an ultra-high-field system and improved volume and mix.

Bruker Stock Down 1.7%

BRKR stock traded down $0.88 during midday trading on Thursday, hitting $51.59. The company’s stock had a trading volume of 306,728 shares, compared to its average volume of 2,415,924. The company has a market cap of $7.85 billion, a PE ratio of -73.64, a P/E/G ratio of 1.61 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.72 and a debt-to-equity ratio of 0.76. The firm’s 50-day moving average is $58.67 and its 200-day moving average is $46.73. Bruker has a 12 month low of $28.53 and a 12 month high of $65.30.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is presently -83.33%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BRKR. Guggenheim raised their price target on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Wolfe Research began coverage on shares of Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. raised their price objective on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. TD Cowen reissued a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Finally, UBS Group set a $60.00 target price on Bruker in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $56.64.

More Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Zacks upgraded Bruker from “Hold” to “Strong Buy,” providing a favorable analyst signal following the company’s quarterly results. Zacks.com
• Positive Sentiment: Bruker reported second-quarter adjusted EPS of $0.49, ahead of the $0.38 consensus, while revenue increased 5.2% year over year to $838.5 million. Management also highlighted margin strength on its earnings call. Bruker Corporation Earnings Call Highlights Margin Strength
• Neutral Sentiment: Bruker’s earnings call and results presentation offered additional detail on the quarter, including improved profitability and ongoing execution, but investors remain focused on the company’s revenue trajectory. Bruker Corporation Q2 2026 Earnings Call Summary
• Negative Sentiment: Revenue fell short of analyst expectations, and Bruker reduced its 2026 reported revenue guidance to $3.54 billion-$3.57 billion from $3.57 billion-$3.60 billion. Management also expects approximately $20 million of semiconductor-related revenue to shift from the third quarter into the fourth quarter. Bruker Falls as Investors Focus on Lower Revenue Outlook and Q3 Timing Shift
• Negative Sentiment: A $134.9 million non-cash goodwill impairment tied to the automation and spatial biology businesses contributed to a GAAP loss. Weak U.S. academic demand and a low-double-digit decline in Asia-Pacific revenue further clouded the outlook. Weak Growth in Bruker’s Primary Market
• Negative Sentiment: Citigroup lowered its price target to $53 from $60 and maintained a “Neutral” rating, signaling limited upside based on the current revenue concerns. Benzinga

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP lifted its stake in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the period. Federated Hermes Inc. raised its position in shares of Bruker by 6.7% during the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after purchasing an additional 380 shares during the last quarter. Parallel Advisors LLC raised its stake in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the period. Los Angeles Capital Management LLC purchased a new position in Bruker during the fourth quarter worth about $26,000. Finally, UMB Bank n.a. increased its holdings in Bruker by 57.9% in the 4th quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 576 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.